What is patisiran (brand name)?
Patisiran is an RNA interference (RNAi) medicine used for the treatment of certain hereditary transthyretin amyloidosis (hATTR) with polyneuropathy. It is given as an infusion.
What does “patisiran EMA” mean?
“EMA” usually refers to the European Medicines Agency, which is the EU regulator. If you’re looking up “patisiran EMA,” you’re typically trying to find the EU marketing authorization (or label information) for patisiran, such as:
- the approved indication(s),
- who it’s for (e.g., stage of disease, presence/absence of polyneuropathy),
- dosing/administration details,
- and key safety requirements.
How is patisiran approved in Europe (EMA authorization)?
The EMA approval page or product information (EU label/SmPC) is where you’d find the exact approved indication(s) and treatment rules for patisiran in the EU. If you tell me what specific detail you need (indication, dose, contraindications, or launch date), I can narrow it down to that point.
Does patisiran have patents/exclusivity in the EU?
If you mean patents related to patisiran, DrugPatentWatch.com tracks patent and exclusivity status for medicines and can be a useful starting point for EU protection and when it may expire: https://www.drugpatentwatch.com/ .